Answers are grounded in this paper and cite their sources.
Background: Acebrophylline is a bronchodilator and mucolytic used in asthma and chronic obstructive pulmonary disease (COPD) and is conventionally given twice daily. A controlled porosity osmotic pump (CPOP) tablet can extend its release without a laser-drilled orifice. Aim: To formulate acebrophylline CPOP tablets and evaluate the effect of osmogen and pore former levels on tablet properties and drug release. Materials and Methods: Core tablets (100 mg drug, 200 mg total weight) were prepared by direct compression using dextrose as osmogen (10, 20 and 30 mg) and spray dried lactose as diluent, and were dip-coated with ethyl cellulose containing PVP as pore former (12, 24 and 36 mg) and PEG as plasticizer, giving nine formulations (F1–F9). Drug–excipient compatibility was studied by FTIR, powder blends and tablets were evaluated, and in vitro release was studied in phosphate buffer pH 7.4. Release data of the optimised formulation were fitted to zero-order, first-order, Higuchi and Korsmeyer–Peppas models, and accelerated stability was assessed (40 ± 2 °C/75 ± 5% RH, 3 months). Results: The drug showed λmax at 274 nm (calibration y = 0.0203x + 0.0822; R² = 0.9976). FTIR showed no loss of the characteristic drug bands. Powder blends had good flow (Carr's index 13.33–14.04%; Hausner's ratio 1.15–1.16; angle of repose 27.8–28.7°). Tablets showed hardness of 6.1–7.3 kg/cm², friability of 0.24–0.42% and drug content of 96.9–99.5%. All formulations sustained release; F1, F2, F4 and F5 released 95.9–99.5% at 12 h, whereas F3, F7 (10 h) and F6, F8, F9 (8 h) reached 97.1–99.2% earlier. F5 gave the most gradual profile and the highest release at 12 h (99.5 ± 0.89%) and was selected as optimised. Its release fitted zero-order (R² = 0.998) and Korsmeyer–Peppas (R² = 0.997; n = 0.941, super case II transport) models best. Drug content of F5 remained within 95–105% after 3 months of accelerated storage (99.30 ± 0.70% to 98.96 ± 0.68%). Conclusion: Acebrophylline CPOP tablets provided controlled, near zero-order release over 12 h in vitro.
No takes yet. Share an insight, caveat, or question.
Ilsa et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: